clinical trial – Page 5

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY 09/16/2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.

OB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY 09/16/2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.

Clinical Updates news Oncology Specialties

Oral Metformin in Non-Muscle-Invasive Bladder Cancer: Insights from a Phase II Marker Lesion Study

By MedXY 09/15/2025

A phase II trial assessing oral metformin for low-grade non-muscle-invasive bladder cancer (NMIBC) found minimal antitumor activity and no significant mechanistic changes, challenging metformin’s role as an intravesical therapeutic agent in this context.

AI Neurology news Specialties

Evaluating AI-Enhanced EMG Reporting: Insights from a Randomized Controlled Trial

By MedXY 09/14/2025

An RCT evaluated an AI-assisted framework for electrodiagnostic report interpretation, finding no significant improvement over standard physician reporting but highlighting potential workflow benefits for routine cases.

Clinical Updates General Surgery Oncology Radiology Specialties

Preoperative versus Postoperative Stereotactic Radiation Therapy for Brain Metastases: Safety, Feasibility, and Efficiency Insights from a Phase 3 Randomized Trial

By MedXY 09/13/2025

A phase 3 randomized trial demonstrates that preoperative stereotactic radiation therapy (SRT) for brain metastases offers comparable safety and reduced treatment duration compared to postoperative SRT, potentially improving patient care logistics.

Clinical Updates Oncology Specialties

High-Dose Aumolertinib Demonstrates Promising Efficacy in Untreated EGFR-Mutant NSCLC with Brain Metastases: Insights from the ACHIEVE Phase 2 Trial

By MedXY 09/11/2025

The ACHIEVE Phase 2 trial reveals that high-dose aumolertinib offers significant intracranial and systemic control with a manageable safety profile in patients with untreated EGFR-mutant NSCLC and brain metastases, highlighting its therapeutic potential.

Anesthesiology OB/GYN & Women's Health Specialties

Transcutaneous Auricular Vagus Nerve Stimulation: A Novel Approach to Managing Postpartum Uterine Contraction Pain after Cesarean Delivery

By MedXY 09/11/2025

A randomized clinical trial shows that transcutaneous auricular vagus nerve stimulation significantly reduces postpartum uterine contraction pain, incisional pain, anxiety, and depression, enhancing recovery and sleep quality in cesarean delivery patients.

news Psychiatry Specialties

Esketamine Monotherapy for Treatment-Resistant Depression: A New Therapeutic Frontier

By MedXY 09/11/2025

A phase 4 randomized trial demonstrates that esketamine nasal spray monotherapy significantly reduces depressive symptoms in adults with treatment-resistant depression, offering a promising alternative to oral antidepressants.

Neurology Specialties

Evaluating Intra-Arterial Tenecteplase Post-Thrombectomy in Large Vessel Occlusion Stroke: Safety and Early Efficacy from a Dose-Escalation Randomized Trial

By MedXY 09/11/2025

Adjunctive intra-arterial tenecteplase after successful reperfusion in anterior circulation large vessel occlusion stroke demonstrates an acceptable safety profile at low doses, supporting further investigation into its therapeutic potential.

Cardiology Clinical Updates Specialties

Medication Adherence in Hypertension: Insights from the TEAMLET Cluster Randomized Clinical Trial and Related Advances

By MedXY 09/11/2025

TEAMLET trial reveals limited impact of EHR-pharmacy linked interventions on medication adherence in hypertension, highlighting complexity of adherence barriers and the need for multifaceted, patient-centered strategies.

Cardiology news Specialties

Evaluating Mavacamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Insights from the ODYSSEY-HCM Trial

By MedXY 09/10/2025

A phase 3 trial found mavacamten did not significantly improve exercise capacity or symptoms in adults with symptomatic nonobstructive hypertrophic cardiomyopathy compared to placebo, despite its efficacy in obstructive HCM.

General Surgery Oncology Specialties

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

By MedXY 09/10/2025

The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.

OB/GYN & Women's Health Oncology Specialties

ADAGIO Trial Illuminates Adavosertib’s Potential in Recurrent Uterine Serous Carcinoma Amidst Safety Challenges

By MedXY 09/09/2025

The ADAGIO phase IIb study assessed adavosertib in recurrent uterine serous carcinoma post-platinum therapy, revealing modest efficacy and significant toxicity, with biomarker trends suggesting CCNE1/cyclin E1 as potential response predictors.

Clinical Updates Oncology Specialties

Efficacy and Challenges of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors: Insights from the Alliance A021202 Trial

By MedXY 09/08/2025

The randomized phase II Alliance A021202 trial demonstrated that pazopanib significantly improves progression-free survival in advanced extrapancreatic neuroendocrine tumors, confirming VEGF pathway as a therapeutic target but highlighting safety concerns that preclude further development.

Cardiology Clinical Updates Public Health Specialties

PANDA II Trial Confirms Influenza Vaccination as Essential Intervention for Acute Heart Failure Patients

By MedXY 09/03/2025

The PANDA II study demonstrates that influenza vaccination significantly reduces mortality and rehospitalization in acute heart failure patients, supporting its inclusion as a standard component of heart failure management worldwide.

Cardiology Clinical Updates news Specialties

Five Key Lessons From the DIGIT-HF Trial: Revisiting Digitoxin in HFrEF Management

By MedXY 08/30/2025

The DIGIT-HF trial sheds new light on digitoxin's role in heart failure with reduced ejection fraction, revealing safety, efficacy, and clinical implications despite contemporary therapies.

Clinical Updates Hematology-Oncology news Specialties

Optimizing Therapy in Transplant-Ineligible Multiple Myeloma: Insights from the REST Phase 2 Trial on Isatuximab, Bortezomib, Lenalidomide, and Limited Dexamethasone

By MedXY 08/30/2025

The REST trial demonstrated that combining isatuximab with weekly bortezomib, lenalidomide, and limited dexamethasone yields promising efficacy and manageable safety in older patients with transplant-ineligible multiple myeloma.

Diabetes & Endocrinology Specialties

CagriSema: A Breakthrough Combination Therapy for Weight Loss in Adults with Overweight or Obesity

By MedXY 08/28/2025

A phase 3a trial shows coadministered cagrilintide and semaglutide (CagriSema) significantly reduce body weight up to 20.4% over 68 weeks in adults with overweight or obesity, with manageable side effects, offering a promising new option for obesity management.

Allergy & Immunology Clinical Updates news Respiratory Specialties

Rentosertib: The First AI-Discovered TNIK Inhibitor Shows Promise in Idiopathic Pulmonary Fibrosis Phase 2a Trial

By MedXY 08/27/2025

Rentosertib, an AI-designed TNIK inhibitor, demonstrated safety and preliminary efficacy in idiopathic pulmonary fibrosis in a randomized phase 2a trial, marking a milestone in AI-driven drug development for progressive lung diseases.

$Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis$

Allergy & Immunology Rheumatology Specialties

Dual JAK and ROCK Inhibition with CPL’116: A Promising Advance for Methotrexate-Refractory Rheumatoid Arthritis

By MedXY 08/27/2025

CPL'116, a novel dual JAK and ROCK inhibitor, demonstrates dose-dependent efficacy and a favorable safety profile in rheumatoid arthritis patients inadequately responsive to methotrexate, without the typical lipid or creatine kinase abnormalities associated with JAK inhibitors.